IL-17 and related cytokines involved in the pathology and immunotherapy of multiple sclerosis: Current and future developments

Cytokine and Growth Factor Reviews

Volumn 25, Issue 4, 2014, Pages 403-413

  Luchtman, Dirk W ^a   Ellwardt, Erik ^a   Larochelle, Catherine ^a,b   Zipp, Frauke ^a  

^a UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

^b CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

Author keywords

Cytokines; EAE; Multiple sclerosis; Th17; Therapy

Indexed keywords

ANTIBODY; BETA INTERFERON; BRIAKINUMAB; CJM 112; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 17; INTERLEUKIN 1BETA; INTERLEUKIN 21; INTERLEUKIN 22; INTERLEUKIN 23; INTERLEUKIN 6; MOR 103; PLACEBO; SECUKINUMAB; TOCILIZUMAB; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; AUTACOID; IL17A PROTEIN, HUMAN;

ANTIBODY TITER; AUTOIMMUNITY; CYTOKINE PRODUCTION; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; FEVER; GENE INDUCTION; HEADACHE; HUMAN; IMMUNOTHERAPY; INJECTION SITE INFLAMMATION; MULTIPLE SCLEROSIS; MYALGIA; NAUSEA; PATHOGENESIS; PSORIASIS; RHEUMATOID ARTHRITIS; SHORT SURVEY; T LYMPHOCYTE SUBPOPULATION; TH17 CELL; ANIMAL; CELL DIFFERENTIATION; CENTRAL NERVOUS SYSTEM; CYTOLOGY; IMMUNOLOGY; MOUSE; PATHOLOGY; PROCEDURES;

ANIMALS; AUTOIMMUNITY; CELL DIFFERENTIATION; CENTRAL NERVOUS SYSTEM; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; HUMANS; IMMUNOTHERAPY; INFLAMMATION MEDIATORS; INTERFERON-BETA; INTERLEUKIN-17; MICE; MULTIPLE SCLEROSIS; TH17 CELLS;

EID: 84908022527     PISSN: 13596101     EISSN: 18790305     Source Type: Journal    
DOI: 10.1016/j.cytogfr.2014.07.013     Document Type: Short Survey

References (185)

1. Ellwardt E., Zipp F. Molecular mechanisms linking neuroinflammation and neurodegeneration in MS. Exp Neurol 2014, 10.1016/j.expneurol.2014.02.006.
2. Koch-Henriksen N., Sorensen P.S. The changing demographic pattern of multiple sclerosis epidemiology. Lancet Neurol 2010, 9:520-532.
3. Siffrin V., Vogt J., Radbruch H., Nitsch R., Zipp F. Multiple sclerosis-candidate mechanisms underlying CNS atrophy. Trends Neurosci 2010, 33:202-210.
4. Zipp F., Gold R., Wiendl H. Identification of inflammatory neuronal injury and prevention of neuronal damage in multiple sclerosis: hope for novel therapies?. JAMA Neurol 2013, 70:1569-1574.
5. Stys P.K., Zamponi G.W., van Minnen J., Geurts J.J. Will the real multiple sclerosis please stand up?. Nat Rev Neurosci 2012, 13:507-514.
6. Sibley W.A., Bamford C.R., Clark K. Clinical viral infections and multiple sclerosis. Lancet 1985, 1:1313-1315.
7. Kurtzke J.F. Epidemiology in multiple sclerosis: a pilgrim's progress. Brain 2013, 136:2904-2917.
8. Beecham A.H., Patsopoulos N.A., Xifara D.K., Davis M.F., Kemppinen A., et al. Analysis of immune-related loci identifies 48 new susceptibility variants for multiple sclerosis. Nat Genet 2013, 45:1353-1360. International Multiple Sclerosis Genetics C.
9. Aktas O., Smorodchenko A., Brocke S., Infante-Duarte C., Schulze Topphoff U., Vogt J., et al. Neuronal damage in autoimmune neuroinflammation mediated by the death ligand TRAIL. Neuron 2005, 46:421-432.
10. Steinman L. A brief history of T(H)17, the first major revision in the T(H)1/T(H)2 hypothesis of T cell-mediated tissue damage. Nat Med 2007, 13:139-145.
11. Oppmann B., Lesley R., Blom B., Timans J.C., Xu Y., Hunte B., et al. Novel p19 protein engages IL-12p40 to form a cytokine, IL-23, with biological activities similar as well as distinct from IL-12. Immunity 2000, 13:715-725.
12. Cua D.J., Sherlock J., Chen Y., Murphy C.A., Joyce B., Seymour B., et al. Interleukin-23 rather than interleukin-12 is the critical cytokine for autoimmune inflammation of the brain. Nature 2003, 421:744-748.
13. Harrington L.E., Hatton R.D., Mangan P.R., Turner H., Murphy T.L., Murphy K.M., et al. Interleukin 17-producing CD4+ effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages. Nat Immunol 2005, 6:1123-1132.
14. Korn T., Bettelli E., Oukka M., Kuchroo V.K. IL-17 and Th17 Cells. Annu Rev Immunol 2009, 27:485-517.
15. Sie C., Korn T., Mitsdoerffer M. Th17 cells in central nervous system autoimmunity. Exp Neurol 2014, 10.1016/j.expneurol.2014.03.009.
16. Traugott U., Lebon P. Multiple sclerosis: involvement of interferons in lesion pathogenesis. Ann Neurol 1988, 24:243-251.
17. Traugott U., Lebon P. Demonstration of alpha, beta, and gamma interferon in active chronic multiple sclerosis lesions. Ann N Y Acad Sci 1988, 540:309-311.
18. Panitch H.S., Hirsch R.L., Haley A.S., Johnson K.P. Exacerbations of multiple sclerosis in patients treated with gamma interferon. Lancet 1987, 1:893-895.
19. Leonard J.P., Waldburger K.E., Goldman S.J. Prevention of experimental autoimmune encephalomyelitis by antibodies against interleukin 12. J Exp Med 1995, 181:381-386.
20. Smith T., Hewson A.K., Kingsley C.I., Leonard J.P., Cuzner M.L. Interleukin-12 induces relapse in experimental allergic encephalomyelitis in the Lewis rat. Am J Pathol 1997, 150:1909-1917.
21. Renno T., Taupin V., Bourbonniere L., Verge G., Tran E., De Simone R., et al. Interferon-gamma in progression to chronic demyelination and neurological deficit following acute EAE. Mol Cell Neurosci 1998, 12:376-389.
22. Vartanian T., Li Y., Zhao M., Stefansson K. Interferon-gamma-induced oligodendrocyte cell death: implications for the pathogenesis of multiple sclerosis. Mol Med 1995, 1:732-743.
23. Tomioka R., Matsui M. Biomarkers for multiple sclerosis. Intern Med 2014, 53:361-365.
24. Bartosik-Psujek H., Magrys A., Montewka-Koziol M., Stelmasiak Z. [Change of interleukin-4 and interleukin-12 levels after therapy of multiple sclerosis relapse with methylprednisolone]. Neurol Neurochir Pol 2005, 39:207-212.
25. Ferber I.A., Brocke S., Taylor-Edwards C., Ridgway W., Dinisco C., Steinman L., et al. Mice with a disrupted IFN-gamma gene are susceptible to the induction of experimental autoimmune encephalomyelitis (EAE). J Immunol 1996, 156:5-7.
26. Willenborg D.O., Fordham S., Bernard C.C., Cowden W.B., Ramshaw I.A. IFN-gamma plays a critical down-regulatory role in the induction and effector phase of myelin oligodendrocyte glycoprotein-induced autoimmune encephalomyelitis. J Immunol 1996, 157:3223-3227.
27. Becher B., Durell B.G., Noelle R.J. Experimental autoimmune encephalitis and inflammation in the absence of interleukin-12. J Clin Invest 2002, 110:493-497.
28. Gran B., Zhang G.X., Yu S., Li J., Chen X.H., Ventura E.S., et al. IL-12p35-deficient mice are susceptible to experimental autoimmune encephalomyelitis: evidence for redundancy in the IL-12 system in the induction of central nervous system autoimmune demyelination. J Immunol 2002, 169:7104-7110.
29. Aggarwal S., Ghilardi N., Xie M.H., de Sauvage F.J., Gurney A.L. Interleukin-23 promotes a distinct CD4 T cell activation state characterized by the production of interleukin-17. J Biol Chem 2003, 278:1910-1914.
30. Murphy C.A., Langrish C.L., Chen Y., Blumenschein W., McClanahan T., Kastelein R.A., et al. Divergent pro- and antiinflammatory roles for IL-23 and IL-12 in joint autoimmune inflammation. J Exp Med 2003, 198:1951-1957.
31. Langrish C.L., Chen Y., Blumenschein W.M., Mattson J., Basham B., Sedgwick J.D., et al. IL-23 drives a pathogenic T cell population that induces autoimmune inflammation. J Exp Med 2005, 201:233-240.
32. Yang X.O., Pappu B.P., Nurieva R., Akimzhanov A., Kang H.S., Chung Y., et al. T helper 17 lineage differentiation is programmed by orphan nuclear receptors ROR alpha and ROR gamma. Immunity 2008, 28:29-39.
33. Bettelli E., Carrier Y., Gao W., Korn T., Strom T.B., Oukka M., et al. Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature 2006, 441:235-238.
34. Calabresi P.A., Fields N.S., Maloni H.W., Hanham A., Carlino J., Moore J., et al. Phase 1 trial of transforming growth factor beta 2 in chronic progressive MS. Neurology 1998, 51:289-292.
35. Mangan P.R., Harrington L.E., O'Quinn D.B., Helms W.S., Bullard D.C., Elson C.O., et al. Transforming growth factor-beta induces development of the T(H)17 lineage. Nature 2006, 441:231-234.
36. Veldhoen M., Hocking R.J., Atkins C.J., Locksley R.M., Stockinger B. TGFbeta in the context of an inflammatory cytokine milieu supports de novo differentiation of IL-17-producing T cells. Immunity 2006, 24:179-189.
37. Korn T., Bettelli E., Gao W., Awasthi A., Jager A., Strom T.B., et al. IL-21 initiates an alternative pathway to induce proinflammatory T(H)17 cells. Nature 2007, 448:484-487.
38. McGeachy M.J., Chen Y., Tato C.M., Laurence A., Joyce-Shaikh B., Blumenschein W.M., et al. The interleukin 23 receptor is essential for the terminal differentiation of interleukin 17-producing effector T helper cells in vivo. Nat Immunol 2009, 10:314-324.
39. Reiner S.L. Development in motion: helper T cells at work. Cell 2007, 129:33-36.
40. Nurieva R., Yang X.O., Martinez G., Zhang Y., Panopoulos A.D., Ma L., et al. Essential autocrine regulation by IL-21 in the generation of inflammatory T cells. Nature 2007, 448:480-483.
41. Zhou L., Ivanov I.I., Spolski R., Min R., Shenderov K., Egawa T., et al. IL-6 programs T(H)-17 cell differentiation by promoting sequential engagement of the IL-21 and IL-23 pathways. Nat Immunol 2007, 8:967-974.
42. Volpe E., Servant N., Zollinger R., Bogiatzi S.I., Hupe P., Barillot E., et al. A critical function for transforming growth factor-beta, interleukin 23 and proinflammatory cytokines in driving and modulating human T(H)-17 responses. Nat Immunol 2008, 9:650-657.
43. Ghoreschi K., Laurence A., Yang X.P., Tato C.M., McGeachy M.J., Konkel J.E., et al. Generation of pathogenic T(H)17 cells in the absence of TGF-beta signalling. Nature 2010, 467:967-971.
44. Lee Y., Awasthi A., Yosef N., Quintana F.J., Xiao S., Peters A., et al. Induction and molecular signature of pathogenic TH17 cells. Nat Immunol 2012, 13:991-999.
45. McGeachy M.J., Cua D.J. The link between IL-23 and Th17 cell-mediated immune pathologies. Semin Immunol 2007, 19:372-376.
46. Croxford A.L., Mair F., Becher B. IL-23: one cytokine in control of autoimmunity. Eur J Immunol 2012, 42:2263-2273.
47. Quintana F.J., Basso A.S., Iglesias A.H., Korn T., Farez M.F., Bettelli E., et al. Control of T(reg) and T(H)17 cell differentiation by the aryl hydrocarbon receptor. Nature 2008, 453:65-71.
48. Perdew G.H., Babbs C.F. Production of Ah receptor ligands in rat fecal suspensions containing tryptophan or indole-3-carbinol. Nutr Cancer 1991, 16:209-218.
49. Wikoff W.R., Anfora A.T., Liu J., Schultz P.G., Lesley S.A., Peters E.C., et al. Metabolomics analysis reveals large effects of gut microflora on mammalian blood metabolites. Proc Natl Acad Sci U S A 2009, 106:3698-3703.
50. Berer K., Krishnamoorthy G. Commensal gut flora and brain autoimmunity: a love or hate affair?. Acta Neuropathol 2012, 123:639-651.
51. Fasano A., Shea-Donohue T. Mechanisms of disease: the role of intestinal barrier function in the pathogenesis of gastrointestinal autoimmune diseases. Nat Clin Pract Gastroenterol Hepatol 2005, 2:416-422.
52. Ochoa-Reparaz J., Mielcarz D.W., Ditrio L.E., Burroughs A.R., Foureau D.M., Haque-Begum S., et al. Role of gut commensal microflora in the development of experimental autoimmune encephalomyelitis. J Immunol 2009, 183:6041-6050.
53. Lavasani S., Dzhambazov B., Nouri M., Fak F., Buske S., Molin G., et al. A novel probiotic mixture exerts a therapeutic effect on experimental autoimmune encephalomyelitis mediated by IL-10 producing regulatory T cells. PLoS One 2010, 5:e9009.
54. Ivanov I.I., Atarashi K., Manel N., Brodie E.L., Shima T., Karaoz U., et al. Induction of intestinal Th17 cells by segmented filamentous bacteria. Cell 2009, 139:485-498.
55. Lee Y.K., Menezes J.S., Umesaki Y., Mazmanian S.K. Proinflammatory T-cell responses to gut microbiota promote experimental autoimmune encephalomyelitis. Proc Natl Acad Sci U S A 2011, 108(Suppl 1):4615-4622.
56. Kleinewietfeld M., Manzel A., Titze J., Kvakan H., Yosef N., Linker R.A., et al. Sodium chloride drives autoimmune disease by the induction of pathogenic TH17 cells. Nature 2013, 496:518-522.
57. Wu C., Yosef N., Thalhamer T., Zhu C., Xiao S., Kishi Y., et al. Induction of pathogenic TH17 cells by inducible salt-sensing kinase SGK1. Nature 2013, 496:513-517.
58. Lee Y., Collins M., Kuchroo V.K. Unexpected targets and triggers of autoimmunity. J Clin Immunol 2014.
59. Kebir H., Ifergan I., Alvarez J.I., Bernard M., Poirier J., Arbour N., et al. Preferential recruitment of interferon-gamma-expressing TH17 cells in multiple sclerosis. Ann Neurol 2009, 66:390-402.
60. Miossec P., Kolls J.K. Targeting IL-17 and TH17 cells in chronic inflammation. Nat Rev Drug Discov 2012, 11:763-776.
61. Larochelle C., Cayrol R., Kebir H., Alvarez J.I., Lecuyer M.A., Ifergan I., et al. Melanoma cell adhesion molecule identifies encephalitogenic T lymphocytes and promotes their recruitment to the central nervous system. Brain 2012, 135:2906-2924.
62. El-Behi M., Ciric B., Dai H., Yan Y., Cullimore M., Safavi F., et al. The encephalitogenicity of T(H)17 cells is dependent on IL-1- and IL-23-induced production of the cytokine GM-CSF. Nat Immunol 2011, 12:568-575.
63. Codarri L., Gyulveszi G., Tosevski V., Hesske L., Fontana A., Magnenat L., et al. RORgammat drives production of the cytokine GM-CSF in helper T cells, which is essential for the effector phase of autoimmune neuroinflammation. Nat Immunol 2011, 12:560-567.
64. Ghoreschi K., Laurence A., Yang X.P., Hirahara K., O'Shea J.J. T helper 17 cell heterogeneity and pathogenicity in autoimmune disease. Trends Immunol 2011, 32:395-401.
65. Reboldi A., Coisne C., Baumjohann D., Benvenuto F., Bottinelli D., Lira S., et al. C-C chemokine receptor 6-regulated entry of TH-17 cells into the CNS through the choroid plexus is required for the initiation of EAE. Nat Immunol 2009, 10:514-523.
66. Hirota K., Duarte J.H., Veldhoen M., Hornsby E., Li Y., Cua D.J., et al. Fate mapping of IL-17-producing T cells in inflammatory responses. Nat Immunol 2011, 12:255-263.
67. Krakauer M., Sorensen P., Khademi M., Olsson T., Sellebjerg F. Increased IL-10 mRNA and IL-23 mRNA expression in multiple sclerosis: interferon-beta treatment increases IL-10 mRNA expression while reducing IL-23 mRNA expression. Mult Scler 2008, 14:622-630.
68. Alexander J.S., Harris M.K., Wells S.R., Mills G., Chalamidas K., Ganta V.C., et al. Alterations in serum MMP-8, MMP-9, IL-12p40 and IL-23 in multiple sclerosis patients treated with interferon-beta1b. Mult Scler 2010, 16:801-809.
69. Li Y., Chu N., Hu A., Gran B., Rostami A., Zhang G.X. Increased IL-23p19 expression in multiple sclerosis lesions and its induction in microglia. Brain 2007, 130:490-501.
70. Maimone D., Gregory S., Arnason B.G., Reder A.T. Cytokine levels in the cerebrospinal fluid and serum of patients with multiple sclerosis. J Neuroimmunol 1991, 32:67-74.
71. Gijbels K., Van Damme J., Proost P., Put W., Carton H., Billiau A. Interleukin 6 production in the central nervous system during experimental autoimmune encephalomyelitis. Eur J Immunol 1990, 20:233-235.
72. Schneider A., Long S.A., Cerosaletti K., Ni C.T., Samuels P., Kita M., et al. In active relapsing-remitting multiple sclerosis, effector T cell resistance to adaptive T(regs) involves IL-6-mediated signaling. Sci Transl Med 2013, 5. 170ra15.
73. Barr T.A., Shen P., Brown S., Lampropoulou V., Roch T., Lawrie S., et al. B cell depletion therapy ameliorates autoimmune disease through ablation of IL-6-producing B cells. J Exp Med 2012, 209:1001-1010.
74. Neurath M.F., Finotto S. IL-6 signaling in autoimmunity, chronic inflammation and inflammation-associated cancer. Cytokine Growth Factor Rev 2011, 22:83-89.
75. Uzawa A., Mori M., Ito M., Uchida T., Hayakawa S., Masuda S., et al. Markedly increased CSF interleukin-6 levels in neuromyelitis optica, but not in multiple sclerosis. J Neurol 2009, 256:2082-2084.
76. Yao X., Huang J., Zhong H., Shen N., Faggioni R., Fung M., et al. Targeting interleukin-6 in inflammatory autoimmune diseases and cancers. Pharmacol Ther 2014, 141:125-139.
77. Jin J.O., Han X., Yu Q. Interleukin-6 induces the generation of IL-10-producing Tr1 cells and suppresses autoimmune tissue inflammation. J Autoimmun 2013, 40:28-44.
78. Matusevicius D., Kivisakk P., He B., Kostulas N., Ozenci V., Fredrikson S., et al. Interleukin-17 mRNA expression in blood and CSF mononuclear cells is augmented in multiple sclerosis. Mult Scler 1999, 5:101-104.
79. Kurasawa K., Hirose K., Sano H., Endo H., Shinkai H., Nawata Y., et al. Increased interleukin-17 production in patients with systemic sclerosis. Arthritis Rheumatol 2000, 43:2455-2463.
80. Durelli L., Conti L., Clerico M., Boselli D., Contessa G., Ripellino P., et al. T-helper 17 cells expand in multiple sclerosis and are inhibited by interferon-beta. Ann Neurol 2009, 65:499-509.
81. Brucklacher-Waldert V., Stuerner K., Kolster M., Wolthausen J., Tolosa E. Phenotypical and functional characterization of T helper 17 cells in multiple sclerosis. Brain 2009, 132:3329-3341.
82. Tzartos J.S., Friese M.A., Craner M.J., Palace J., Newcombe J., Esiri M.M., et al. Interleukin-17 production in central nervous system-infiltrating T cells and glial cells is associated with active disease in multiple sclerosis. Am J Pathol 2008, 172:146-155.
83. Kebir H., Kreymborg K., Ifergan I., Dodelet-Devillers A., Cayrol R., Bernard M., et al. Human TH17 lymphocytes promote blood-brain barrier disruption and central nervous system inflammation. Nat Med 2007, 13:1173-1175.
84. Schulze-Topphoff U., Prat A., Prozorovski T., Siffrin V., Paterka M., Herz J., et al. Activation of kinin receptor B1 limits encephalitogenic T lymphocyte recruitment to the central nervous system. Nat Med 2009, 15:788-793.
85. Siffrin V., Radbruch H., Glumm R., Niesner R., Paterka M., Herz J., et al. In vivo imaging of partially reversible th17 cell-induced neuronal dysfunction in the course of encephalomyelitis. Immunity 2010, 33:424-436.
86. Haak S., Croxford A.L., Kreymborg K., Heppner F.L., Pouly S., Becher B., et al. IL-17A and IL-17F do not contribute vitally to autoimmune neuro-inflammation in mice. J Clin Invest 2009, 119:61-69.
87. Kroenke M.A., Segal B.M. IL-23 modulated myelin-specific T cells induce EAE via an IFNgamma driven, IL-17 independent pathway. Brain Behav Immun 2011, 25:932-937.
88. Komiyama Y., Nakae S., Matsuki T., Nambu A., Ishigame H., Kakuta S., et al. IL-17 plays an important role in the development of experimental autoimmune encephalomyelitis. J Immunol 2006, 177:566-573.
89. Mardiguian S., Serres S., Ladds E., Campbell S.J., Wilainam P., McFadyen C., et al. Anti-IL-17A treatment reduces clinical score and VCAM-1 expression detected by in vivo magnetic resonance imaging in chronic relapsing EAE ABH mice. Am J Pathol 2013, 182:2071-2081.
90. Trajkovic V., Stosic-Grujicic S., Samardzic T., Markovic M., Miljkovic D., Ramic Z., et al. Interleukin-17 stimulates inducible nitric oxide synthase activation in rodent astrocytes. J Neuroimmunol 2001, 119:183-191.
91. Ma X., Reynolds S.L., Baker B.J., Li X., Benveniste E.N., Qin H. IL-17 enhancement of the IL-6 signaling cascade in astrocytes. J Immunol 2010, 184:4898-4906.
92. Kawanokuchi J., Shimizu K., Nitta A., Yamada K., Mizuno T., Takeuchi H., et al. Production and functions of IL-17 in microglia. J Neuroimmunol 2008, 194:54-61.
93. Das Sarma J., Ciric B., Marek R., Sadhukhan S., Caruso M.L., Shafagh J., et al. Functional interleukin-17 receptor A is expressed in central nervous system glia and upregulated in experimental autoimmune encephalomyelitis. J Neuroinflamm 2009, 6:14.
94. Huppert J., Closhen D., Croxford A., White R., Kulig P., Pietrowski E., et al. Cellular mechanisms of IL-17-induced blood-brain barrier disruption. FASEB J 2010, 24:1023-1034.
95. Larochelle C., Alvarez J.I., Prat A. How do immune cells overcome the blood-brain barrier in multiple sclerosis?. FEBS Lett 2011, 585:3770-3780.
96. Griffin G.K., Newton G., Tarrio M.L., Bu D.X., Maganto-Garcia E., Azcutia V., et al. IL-17 and TNF-alpha sustain neutrophil recruitment during inflammation through synergistic effects on endothelial activation. J Immunol 2012, 188:6287-6299.
97. Paintlia M.K., Paintlia A.S., Singh A.K., Singh I. Synergistic activity of interleukin-17 and tumor necrosis factor-alpha enhances oxidative stress-mediated oligodendrocyte apoptosis. J Neurochem 2011, 116:508-521.
98. Peters A., Pitcher L.A., Sullivan J.M., Mitsdoerffer M., Acton S.E., Franz B., et al. Th17 cells induce ectopic lymphoid follicles in central nervous system tissue inflammation. Immunity 2011, 35:986-996.
99. Magliozzi R., Howell O., Vora A., Serafini B., Nicholas R., Puopolo M., et al. Meningeal B-cell follicles in secondary progressive multiple sclerosis associate with early onset of disease and severe cortical pathology. Brain 2007, 130:1089-1104.
100. Perrella O., Carrieri P.B., De Mercato R., Buscaino G.A. Markers of activated T lymphocytes and T cell receptor gamma/delta+ in patients with multiple sclerosis. Eur Neurol 1993, 33:152-155.
101. Carrieri P.B., Provitera V., De Rosa T., Tartaglia G., Gorga F., Perrella O. Profile of cerebrospinal fluid and serum cytokines in patients with relapsing-remitting multiple sclerosis: a correlation with clinical activity. Immunopharmacol Immunotoxicol 1998, 20:373-382.
102. McQualter J.L., Darwiche R., Ewing C., Onuki M., Kay T.W., Hamilton J.A., et al. Granulocyte macrophage colony-stimulating factor: a new putative therapeutic target in multiple sclerosis. J Exp Med 2001, 194:873-882.
103. Ponomarev E.D., Shriver L.P., Maresz K., Pedras-Vasconcelos J., Verthelyi D., Dittel B.N. GM-CSF production by autoreactive T cells is required for the activation of microglial cells and the onset of experimental autoimmune encephalomyelitis. J Immunol 2007, 178:39-48.
104. Gasson J.C. Molecular physiology of granulocyte-macrophage colony-stimulating factor. Blood 1991, 77:1131-1145.
105. Sonderegger I., Iezzi G., Maier R., Schmitz N., Kurrer M., Kopf M. GM-CSF mediates autoimmunity by enhancing IL-6-dependent Th17 cell development and survival. J Exp Med 2008, 205:2281-2294.
106. Franzen R., Bouhy D., Schoenen J. Nervous system injury: focus on the inflammatory cytokine 'granulocyte-macrophage colony stimulating factor'. Neurosci Lett 2004, 361:76-78.
107. Beauvillain C., Donnou S., Jarry U., Scotet M., Gascan H., Delneste Y., et al. Neonatal and adult microglia cross-present exogenous antigens. Glia 2008, 56:69-77.
108. Kosloski L.M., Kosmacek E.A., Olson K.E., Mosley R.L., Gendelman H.E. GM-CSF induces neuroprotective and anti-inflammatory responses in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine intoxicated mice. J Neuroimmunol 2013, 265:1-10.
109. Schabitz W.R., Kruger C., Pitzer C., Weber D., Laage R., Gassler N., et al. A neuroprotective function for the hematopoietic protein granulocyte-macrophage colony stimulating factor (GM-CSF). J Cereb Blood Flow Metab 2008, 28:29-43.
110. Rossi S., Motta C., Studer V., Barbieri F., Buttari F., Bergami A., et al. Tumor necrosis factor is elevated in progressive multiple sclerosis and causes excitotoxic neurodegeneration. Mult Scler 2014, 20:304-312.
111. Bitsch A., Kuhlmann T., Da Costa C., Bunkowski S., Polak T., Bruck W. Tumour necrosis factor alpha mRNA expression in early multiple sclerosis lesions: correlation with demyelinating activity and oligodendrocyte pathology. Glia 2000, 29:366-375.
112. Buntinx M., Moreels M., Vandenabeele F., Lambrichts I., Raus J., Steels P., et al. Cytokine-induced cell death in human oligodendroglial cell lines: I. Synergistic effects of IFN-gamma and TNF-alpha on apoptosis. J Neurosci Res 2004, 76:834-845.
113. van Oosten B.W., Barkhof F., Truyen L., Boringa J.B., Bertelsmann F.W., von Blomberg B.M., Increased M.R.I., et al. activity and immune activation in two multiple sclerosis patients treated with the monoclonal anti-tumor necrosis factor antibody cA2. Neurology 1996, 47:1531-1534.
114. The Lenercept Multiple Sclerosis Study Group and The University of British Columbia MS/MRI Analysis Group. TNF neutralization in MS: results of a randomized, placebo-controlled multicenter study. The Lenercept Multiple Sclerosis Study Group and The University of British Columbia MS/MRI Analysis Group. Neurology. 1999; 53:457-65.
115. Locksley R.M., Killeen N., Lenardo M.J. The TNF and TNF receptor superfamilies: integrating mammalian biology. Cell 2001, 104:487-501.
116. Nagyoszi P., Wilhelm I., Farkas A.E., Fazakas C., Dung N.T., Hasko J., et al. Expression and regulation of toll-like receptors in cerebral endothelial cells. Neurochem Int 2010, 57:556-564.
117. McCoy M.K., Tansey M.G. TNF signaling inhibition in the CNS: implications for normal brain function and neurodegenerative disease. J Neuroinflamm 2008, 5:45.
118. Schoenborn J.R., Wilson C.B. Regulation of interferon-gamma during innate and adaptive immune responses. Adv Immunol 2007, 96:41-101.
119. Shrikant P., Benveniste E.N. The central nervous system as an immunocompetent organ: role of glial cells in antigen presentation. J Immunol 1996, 157:1819-1822.
120. Neumann H., Medana I.M., Bauer J., Lassmann H. Cytotoxic T lymphocytes in autoimmune and degenerative CNS diseases. Trends Neurosci 2002, 25:313-319.
121. Hashioka S., Klegeris A., Qing H., McGeer P.L. STAT3 inhibitors attenuate interferon-gamma-induced neurotoxicity and inflammatory molecule production by human astrocytes. Neurobiol Dis 2011, 41:299-307.
122. Balabanov R., Beaumont T., Dore-Duffy P. Role of central nervous system microvascular pericytes in activation of antigen-primed splenic T-lymphocytes. J Neurosci Res 1999, 55:578-587.
123. Pierson E., Simmons S.B., Castelli L., Goverman J.M. Mechanisms regulating regional localization of inflammation during CNS autoimmunity. Immunol Rev 2012, 248:205-215.
124. Millward J.M., Lobner M., Wheeler R.D., Owens T. Inflammation in the central nervous system and Th17 responses are inhibited by IFN-gamma-Induced IL-18 binding protein. J Immunol 2010, 185:2458-2466.
125. Hara H., Nanri Y., Tabata E., Mitsutake S., Tabira T. Identification of astrocyte-derived immune suppressor factor that induces apoptosis of autoreactive T cells. J Neuroimmunol 2011, 233:135-146.
126. Chu C.Q., Wittmer S., Dalton D.K. Failure to suppress the expansion of the activated CD4 T cell population in interferon gamma-deficient mice leads to exacerbation of experimental autoimmune encephalomyelitis. J Exp Med 2000, 192:123-128.
127. Wingerchuk D.M., Carter J.L. Multiple sclerosis: current and emerging disease-modifying therapies and treatment strategies. Mayo Clin Proc 2014, 89:225-240.
128. McGraw C.A., Lublin F.D. Interferon beta and glatiramer acetate therapy. Neurotherapeutics 2013, 10:2-18.
129. The IFNB Multiple Sclerosis Study Group. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. The IFNB Multiple Sclerosis Study Group. Neurology. 1993; 43:655-61.
130. Paty D.W., Li D.K. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. II. MRI analysis results of a multicenter, randomized, double-blind, placebo-controlled trial. UBC MS/MRI Study Group and the IFNB Multiple Sclerosis Study Group. Neurology 1993, 43:662-667.
131. The IFNB Multiple Sclerosis Study Group and The University of British Columbia MS/MRI Analysis Group. Interferon beta-1b in the treatment of multiple sclerosis: final outcome of the randomized controlled trial. The IFNB Multiple Sclerosis Study Group and The University of British Columbia MS/MRI Analysis Group. Neurology. 1995;45:1277-85.
132. Li D.K., Paty D.W. Magnetic resonance imaging results of the PRISMS trial: a randomized, double-blind, placebo-controlled study of interferon-beta1a in relapsing-remitting multiple sclerosis. Prevention of Relapses and Disability by Interferon-beta1a Subcutaneously in Multiple Sclerosis. Ann Neurol 1999, 46:197-206.
133. Jacobs L.D., Cookfair D.L., Rudick R.A., Herndon R.M., Richert J.R., Salazar A.M., et al. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis, The Multiple Sclerosis Collaborative Research Group (MSCRG). Ann Neurol 1996, 39:285-294.
134. PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group. Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group. Lancet. 1998;352:1498-504.
135. Larochelle C., Grand'maison F., Bernier G.P., Latour M., Cailhier J.F., Prat A. Thrombotic thrombocytopenic purpura-hemolytic uremic syndrome in relapsing-remitting multiple sclerosis patients on high-dose interferon beta. Mult Scler 2014.
136. Axtell R.C., Raman C. Janus-like effects of type I interferon in autoimmune diseases. Immunol Rev 2012, 248:23-35.
137. Dhib-Jalbut S., Marks S. Interferon-beta mechanisms of action in multiple sclerosis. Neurology 2010, 74(Suppl 1):S17-S24.
138. Ramgolam V.S., Sha Y., Jin J., Zhang X., Markovic-Plese S. IFN-beta inhibits human Th17 cell differentiation. J Immunol 2009, 183:5418-5427.
139. Guo B., Chang E.Y., Cheng G. The type I IFN induction pathway constrains Th17-mediated autoimmune inflammation in mice. J Clin Invest 2008, 118:1680-1690.
140. Axtell R.C., de Jong B.A., Boniface K., van der Voort L.F., Bhat R., De Sarno P., et al. T helper type 1 and 17 cells determine efficacy of interferon-beta in multiple sclerosis and experimental encephalomyelitis. Nat Med 2010, 16:406-412.
141. Reder A.T., Velichko S., Yamaguchi K.D., Hamamcioglu K., Ku K., Beekman J., et al. IFN-beta1b induces transient and variable gene expression in relapsing-remitting multiple sclerosis patients independent of neutralizing antibodies or changes in IFN receptor RNA expression. J Interferon Cytokine Res 2008, 28:317-331.
142. Axtell R.C., Raman C., Steinman L. Interferon-beta exacerbates Th17-mediated inflammatory disease. Trends Immunol 2011, 32:272-277.
143. Axtell R.C., Steinman L. Type 1 interferons cool the inflamed brain. Immunity 2008, 28:600-602.
144. Noseworthy J.H., Lucchinetti C., Rodriguez M., Weinshenker B.G. Multiple sclerosis. N Engl J Med 2000, 343:938-952.
145. Schwid S.R., Panitch H.S. Full results of the evidence of interferon dose-response-european north american comparative efficacy (EVIDENCE) study: a multicenter, randomized, assessor-blinded comparison of low-dose weekly versus high-dose, high-frequency interferon beta-1a for relapsing multiple sclerosis. Clin Ther 2007, 29:2031-2048.
146. Killestein J., Polman C.H. Determinants of interferon beta efficacy in patients with multiple sclerosis. Nat Rev Neurol 2011, 7:221-228.
147. Pappas D.J., Oksenberg J.R. Multiple sclerosis pharmacogenomics: maximizing efficacy of therapy. Neurology 2010, 74(Suppl 1):S62-S69.
148. Wandinger K.P., Lunemann J.D., Wengert O., Bellmann-Strobl J., Aktas O., Weber A., et al. TNF-related apoptosis inducing ligand (TRAIL) as a potential response marker for interferon-beta treatment in multiple sclerosis. Lancet 2003, 361:2036-2043.
149. Paolicelli D., D'Onghia M., Pellegrini F., Direnzo V., Iaffaldano P., Lavolpe V., et al. The impact of neutralizing antibodies on the risk of disease worsening in interferon beta-treated relapsing multiple sclerosis: a 5 year post-marketing study. J Neurol 2013, 260:1562-1568.
150. Elain G., Jeanneau K., Rutkowska A., Mir A.K., Dev K.K. The selective anti-IL17A monoclonal antibody secukinumab (AIN457) attenuates IL17A-induced levels of IL6 in human astrocytes. Glia 2014, 62:725-735.
151. Araki M., Matsuoka T., Miyamoto K., Kusunoki S., Okamoto T., Murata M., et al. Efficacy of the anti-IL-6 receptor antibody tocilizumab in neuromyelitis optica: a pilot study. Neurology 2014, 82:1302-1306.
152. Dujmovic I., Mangano K., Pekmezovic T., Quattrocchi C., Mesaros S., Stojsavljevic N., et al. The analysis of IL-1 beta and its naturally occurring inhibitors in multiple sclerosis: the elevation of IL-1 receptor antagonist and IL-1 receptor type II after steroid therapy. J Neuroimmunol 2009, 207:101-106.
153. Seppi D., Puthenparampil M., Federle L., Ruggero S., Toffanin E., Rinaldi F., et al. Cerebrospinal fluid IL-1beta correlates with cortical pathology load in multiple sclerosis at clinical onset. J Neuroimmunol 2014, 270:56-60.
154. Rossi S., Studer V., Motta C., Germani G., Macchiarulo G., Buttari F., et al. Cerebrospinal fluid detection of interleukin-1beta in phase of remission predicts disease progression in multiple sclerosis. J Neuroinflamm 2014, 11:32.
155. Moll M., Kuemmerle-Deschner J.B. Inflammasome and cytokine blocking strategies in autoinflammatory disorders. Clin Immunol 2013, 147:242-275.
156. Mondal S., Roy A., Pahan K. Functional blocking monoclonal antibodies against IL-12p40 homodimer inhibit adoptive transfer of experimental allergic encephalomyelitis. J Immunol 2009, 182:5013-5023.
157. Vollmer T.L., Wynn D.R., Alam M.S., Valdes J. A phase 2, 24-week, randomized, placebo-controlled, double-blind study examining the efficacy and safety of an anti-interleukin-12 and -23 monoclonal antibody in patients with relapsing-remitting or secondary progressive multiple sclerosis. Mult Scler 2011, 17:181-191.
158. Segal B.M., Constantinescu C.S., Raychaudhuri A., Kim L., Fidelus-Gort R., Kasper L.H. Repeated subcutaneous injections of IL12/23 p40 neutralising antibody, ustekinumab, in patients with relapsing-remitting multiple sclerosis: a phase II, double-blind, placebo-controlled, randomised, dose-ranging study. Lancet Neurol 2008, 7:796-804.
159. Kucukali C.I., Kurtuncu M., Coban A., Cebi M., Tuzun E. Epigenetics of multiple sclerosis: an updated review. Neuromol Med 2014.
160. Correale J., Ysrraelit M.C., Gaitan M.I. Immunomodulatory effects of Vitamin D in multiple sclerosis. Brain 2009, 132:1146-1160.
161. Joshi S., Pantalena L.C., Liu X.K., Gaffen S.L., Liu H., Rohowsky-Kochan C., et al. 1,25-dihydroxyvitamin D(3) ameliorates Th17 autoimmunity via transcriptional modulation of interleukin-17A. Mol Cell Biol 2011, 31:3653-3669.
162. Luchtman D.W., Song C. Cognitive enhancement by omega-3 fatty acids from child-hood to old age: findings from animal and clinical studies. Neuropharmacology 2013, 64:550-565.
163. Luchtman D.W., Meng Q., Song C. Ethyl-eicosapentaenoate (E-EPA) attenuates motor impairments and inflammation in the MPTP-probenecid mouse model of Parkinson's disease. Behav Brain Res 2012, 226:386-396.
164. Farinotti M., Vacchi L., Simi S., Di Pietrantonj C., Brait L., Filippini G. Dietary interventions for multiple sclerosis. Cochrane Database Syst Rev 2012, 12:CD004192.
165. Semerano L., Assier E., Boissier M.C. Anti-cytokine vaccination: a new biotherapy of autoimmunity?. Autoimmun Rev 2012, 11:785-786.
166. Xiao S., Yosef N., Yang J., Wang Y., Zhou L., Zhu C., et al. Small-molecule RORgammat antagonists inhibit T helper 17 cell transcriptional network by divergent mechanisms. Immunity 2014, 40:477-489.
167. Liblau R.S., Gonzalez-Dunia D., Wiendl H., Zipp F. Neurons as targets for T cells in the nervous system. Trends Neurosci 2013, 36:315-324.
168. Golz G., Uhlmann L., Ludecke D., Markgraf N., Nitsch R., Hendrix S. The cytokine/neurotrophin axis in peripheral axon outgrowth. Eur J Neurosci 2006, 24:2721-2730.
169. Fragoso Y.D., Adoni T., Alves-Leon S.V., Azambuja N.D., Barreira A.A., Brooks J.B., et al. Long-term effects of exposure to disease-modifying drugs in the offspring of mothers with multiple sclerosis: a retrospective chart review. CNS Drugs 2013, 27:955-961.
170. Goodin D., Reder A., Ebers G., Cutter G., Kremenchutzky M., Oger J., et al. Survival in MS: a randomized cohort study 21 years after the start of the pivotal IFNβ-1b trial. Neurology 2012, 78:1315-1322.
171. Kieseier B., Calabresi P. PEGylation of Interferon-β-1a. CNS Drugs 2012, 26:205-214.
172. Kappos L., Polman C., Freedman M., Edan G., Hartung H., Miller D., et al. Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes. Neurology 2006, 67:1242-1249.
173. Tintoré M. Rationale for early intervention with immunomodulatory treatments. J Neurology 2008, 255:37-43.
174. Prins M., Eriksson C., Wierinckx A., Bol J.G.J.M., Binnekade R., Tilders F.J.H., et al. Interleukin-1β and interleukin-1 receptor antagonist appear in grey matter additionally to white matter lesions during experimental multiple sclerosis. PLoS ONE 2013, 8:e83835.
175. Badovinac V., Mostarica-Stojković M., Dinarello C.A., Stošić-Grujičić S. Interleukin-1 receptor antagonist suppresses experimental autoimmune encephalomyelitis (EAE) in rats by influencing the activation and proliferation of encephalitogenic cells. J Neuroimmunol 1998, 85:87-95.
176. Orbach R., Gurevich M., Achiron A. Interleukin-12p40 in the spinal fluid as a biomarker for clinically isolated syndrome. Mult Scler 2014, 20:35-42.
177. Raveney B.J.E., Oki S., Yamamura T. Nuclear receptor NR4A2 orchestrates Th17 cell-mediated autoimmune inflammation via IL-21 signalling. PLoS ONE 2013, 8:e56595.
178. Vollmer T.L., Liu R., Price M., Rhodes S., La Cava A., Shi F.-D. Differential effects of IL-21 during initiation and progression of autoimmunity against neuroantigen. J Immunol 2005, 174:2696-2701.
179. Wu A., Zhong X., Wang H., Xu W., Cheng C., Dai Y., et al. Cerebrospinal fluid IL-21 levels in neuromyelitis optica and multiple sclerosis. Can J Neurol Sci 2012, 39:813-820.
180. Tzartos J.S., Craner M.J., Friese M.A., Jakobsen K.B., Newcombe J., Esiri M.M., et al. IL-21 and IL-21 receptor expression in lymphocytes and neurons in multiple sclerosis brain. Am J Pathol 2011, 178:794-802.
181. Kreymborg K., Etzensperger R., Dumoutier L., Haak S., Rebollo A., Buch T., et al. IL-22 is expressed by Th17 cells in an IL-23-dependent fashion, but not required for the development of autoimmune encephalomyelitis. J Immunol 2007, 179:8098-8104.
182. Xu W., li R., Dai Y., Wu A., Wang H., Cheng C., et al. IL-22 secreting CD4+ T cells in the patients with neuromyelitis optica and multiple sclerosis. J Neuroimmunol 2013, 261:87-91.
183. Williams S.K., Maier O., Fischer R., Fairless R., Hochmeister S., Stojic A., et al. Antibody-mediated inhibition of TNFR1 attenuates disease in a mouse model of multiple sclerosis. PLoS ONE 2014, 9:e90117.
184. Glabinski A.R., Bielecki B., Kawczak J.A., Tuohy V.K., Selmaj K., Ransohoff R.M. Treatment with soluble tumor necrosis factor receptor (sTNFR):Fc/p80 fusion protein ameliorates relapsing-remitting experimental autoimmune encephalomyelitis and decreases chemokine expression. Autoimmunity 2004, 37:465-471.
185. Berer K., Mues M., Koutrolos M., Rasbi Z.A., Boziki M., Johner C. et al. Commensal microbiota and myelin autoantigen cooperate to trigger autoimmune demyelination. Nature. 2011, 479:538-541.